Trial Profile

A Phase 1b Study of LY2835219 in Combination With Multiple Single Agent Options for Patients With Stage IV NSCLC

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 13 May 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Abemaciclib (Primary) ; Gemcitabine (Primary) ; Pembrolizumab (Primary) ; Pemetrexed (Primary) ; Ramucirumab (Primary) ; Samotolisib (Primary)
Indications Non-small cell lung cancer
Focus Adverse reactions
Acronyms KEYNOTE-238
Sponsors Eli Lilly and Company

Most Recent Events

18 Nov 2019 Status changed from active, no longer recruiting to completed.
11 Sep 2018 Planned End Date changed from 1 Jul 2020 to 2 Jul 2020.
06 Aug 2018 Planned End Date changed from 1 Jul 2018 to 1 Jul 2020.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com